Resources for coping with cancer during COVID-19. Learn More

Rational Targeting of Prostate Cancer

Presenter: Dr. Mike Cox
Original Date: Tuesday, February 14, 2017

Dr. Cox will provide an overview of:
  • Prostate biology/physiology and an update on prostate cancer epidemiology in Canada.
  • How prostate cancer management has changed since 2010.
  • Emerging concepts of precision oncology and how they are being applied effectively to men with prostate cancer today and in the near future.
  • Recent research being performed on targeting a subtype of prostate cancer that carry TMPRSS2-ERG rearrangements. 

Dr. Mike Cox's Biography:

Dr. Cox is a molecular and cellular biologist who earned his PhD in Biochemistry from the University of North Carolina for studies on how cancer-causing genes normally function to control nerve growth and differentiation.  He began his work on cell signaling networks in cancer as a Research Associate at the University of Virginia.  He has established a research program in Vancouver dedicated to understanding how prostate cancer, the most frequently diagnosed male malignancy, initiates and progresses and to finding ways of halting advanced disease progression. 
Dr. Cox’s research is currently funded by operating grants from the Terry Fox Foundation, Canadian Institute for Health Research and Prostate Cancer Canada. His work focuses on early genetic changes in prostate cells, how resulting tumor cells respond to growth factors in the presence or absence of testosterone and how these cellular changes allow prostate tumor cells to utilize these growth factors to aid development of testosterone independence. 
In conjunction with colleagues at the Vancouver Prostate Centre and University of British Columbia and industrial partnerships, he is developing combinatorial drug strategies that decrease the responsiveness of tumor cells to growth factors and has shown that prostate cancer cells treated in this way are more sensitive to testosterone deprivation or treatment with other chemotherapies. These are first steps in developing effective treatments for patients with advanced prostate cancer.

About Expert Angle

Expert Angle is designed to expand our reach and address the many varied and complex questions that come with a prostate cancer diagnosis. These webinars will address topics important to men with prostate cancer along different points of the cancer care continuum and those within their circle of care as well as the general public and representatives from the clinical community.
The meetings are hosted using interactive on-line technology and feature leading experts in prostate cancer - making them accessible to anyone, regardless of their location, within Canada. The platform allows PCC to communicate directly with individuals in a variety of settings (i.e. in their homes, support group meetings, community centres) and geographic locations (i.e. urban, rural and remote locations) as well as measure engagement.   

View more Expert Angle webinars.


Subscribe to our free monthly e-newsletter!

* indicates required


PCC Spotlight
Canadian Cancer Society and Prostate Cancer Canada celebrate their amalgamation

February 3, 2020 (Toronto, ON) – On the eve of World Cancer Day, the Canadian Cancer Society (CCS) and Prostate Cancer Canada (PCC) have finalized their amalgamation.

1.5 million Canadian men over 50 now at unnecessary risk for prostate cancer

Toronto (ON) – September 26, 2019 – New findings released today in a Prostate Cancer Canada nationwide survey suggest 1.

$2 million invested in new prostate cancer research

Prostate Cancer Canada and Movember partner to fund ten research projects breaking new ground

Dream car draw a win for all Ontarians affected by prostate cancer

February 22, 2019 – TORONTO, ON – A dream came true today for Harold Mutter (ticket #19273), the lucky winner of a 2018 Acura NSX valued at more than $235,000 - the prize for Prostate Cancer Canada’s seventh Rock the Road Raffle.

Click here for news archive